Assertio (ASRT) Scheduled to Post Earnings on Monday

Assertio (NASDAQ:ASRT - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Monday, November 11th. Analysts expect Assertio to post earnings of ($0.04) per share for the quarter. Assertio has set its FY 2024 guidance at EPS.Parties that wish to listen to the company's conference call can do so using this link.

Assertio (NASDAQ:ASRT - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). The company had revenue of $31.13 million during the quarter, compared to analysts' expectations of $30.37 million. Assertio had a negative net margin of 261.08% and a positive return on equity of 4.88%. During the same period last year, the firm earned $0.13 earnings per share. On average, analysts expect Assertio to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Assertio Stock Performance

Shares of Assertio stock traded up $0.03 during trading on Monday, reaching $1.06. The company's stock had a trading volume of 252,074 shares, compared to its average volume of 910,995. The firm has a market cap of $101.06 million, a PE ratio of -0.26 and a beta of 0.83. The company has a 50-day moving average price of $1.17 and a two-hundred day moving average price of $1.17. The company has a current ratio of 1.93, a quick ratio of 1.51 and a debt-to-equity ratio of 0.29. Assertio has a fifty-two week low of $0.73 and a fifty-two week high of $2.37.

Analysts Set New Price Targets

Separately, Maxim Group began coverage on Assertio in a research report on Friday, July 26th. They set a "buy" rating and a $3.00 target price on the stock. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $3.25.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.